Lung Cancer Treatment Advances Reach 60% of US Patients

Lung cancer patients are gaining access to breakthrough treatments faster than ever before, with over 60% now receiving cutting-edge immunotherapy and targeted therapies in the United States.

The progress comes as lung cancer remains one of the deadliest cancers, accounting for 40% to 45% of new cancer diagnoses each year. But new biomarker-driven treatments are changing survival odds for patients at every stage of disease.

Tanja Obradovic, a therapeutic strategy lead in oncology at Novotech, highlighted the rapid pace of innovation following major cancer research conferences in 2026. She noted that advances presented at the American Association of Cancer Research and upcoming American Society of Clinical Oncology meetings are translating into real treatment options for patients nationwide.

The key to these new therapies lies in molecular testing that identifies specific genetic markers in tumors. This testing allows doctors to match patients with targeted drugs designed for their cancer's unique characteristics, dramatically improving outcomes compared to traditional chemotherapy alone.

However, significant gaps remain in getting these treatments to all who need them. Real-world data from 280 US clinics shows less than 60% of patients undergoing treatment for non-small cell lung cancer receive crucial EGFR testing, despite evidence that certain genetic alterations respond poorly to immunotherapy.

Cost and insurance coverage have been major barriers. Testing can take weeks and isn't consistently covered across different insurance plans, delaying treatment for patients with fast-progressing disease.

The Ripple Effect

States are stepping up to close the gap. Fifteen states have now passed laws mandating insurance coverage for comprehensive biomarker testing, ensuring patients can access the diagnostics needed to match them with optimal treatments. Twelve of these state laws extend coverage to Medicaid patients, opening doors for lower-income Americans.

Illinois recently joined this movement, requiring state-regulated health plans and Medicaid to cover biomarker testing supported by medical evidence. These legislative victories are removing financial barriers that previously prevented thousands of patients from accessing precision medicine.

The medical community agrees that comprehensive molecular profiling should now be standard at every stage of lung cancer. With targeted kinase inhibitors proving effective even in early-stage disease, catching the right biomarkers early can mean the difference between standard treatment and a personalized approach with better outcomes.

While the 60% adoption rate for novel therapies in advanced disease represents real progress, advocates emphasize that 40% of patients still aren't receiving these treatments. The gap is even wider in early-stage disease, where biomarker-driven options are just beginning to reach community hospitals.

As insurance coverage expands and testing becomes faster and more accessible, the path from laboratory breakthrough to patient bedside continues to shorten, bringing hope to families facing a lung cancer diagnosis.